Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures

International Journal of Clinical Practice

Volumn 68, Issue 12, 2014, Pages 1503-1507

  Hirsch, Jan D ^a,b   Gnanasakthy, A ^c   Lale, R ^d   Choi, K ^d   Sarkin, A J ^d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; TRIAMCINOLONE ACETONIDE; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GOUT; GOUT IMPACT SCALE; HUMAN; MALE; MULTICENTER STUDY (TOPIC); PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RATING SCALE; RETROSPECTIVE STUDY; SHORT FORM 36; TREATMENT OUTCOME; AGED; ARTHRITIS, GOUTY; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, GOUTY; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE;

EID: 84912038443     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12521     Document Type: Article

References (14)

1. Schlesinger N,. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 2005; 11: S443-50.
2. Schlesinger N, Dalbeth N, Perez-Ruiz F,. Gout: what are the treatment options? Expert Opin Pharmacother 2009; 10: 1319-28.
3. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J,. Gout-Associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
4. Mandell BF,. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 2008; 75: S5-8.
5. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009; 36: 1041-8.
6. Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG,. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10: 308-14.
7. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71: 1839-48.
8. Taylor WJ, Singh JA, Saag KG, et al. Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol 2011; 38: 1467-70.
9. Hirsch JD, Lee SJ, Terkeltaub R, et al. Evaluation of an instrument assessing influence of gout on health-related quality of life. J Rheumatol 2008; 35: 2406-14.
10. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr,. Determining minimally important changes in generic and disease specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478-87.
11. Khanna D, Sarkin AJ, Khanna PP, et al. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford) 2011; 50: 1331-6.
12. Bruce B, Fries JF,. The Stanford health assessment questionnaire (HAQ): a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 167-78.
13. Sarkin AJ, Gnanasakthy A, Lale RS, Choi KJ, Hirsch JD,. A composite endpoint measure to consolidate multidimensional impact of treatment on gouty arthritis. Open J Rheumatol Autoimmun Dis 2013; published online http://www.scirp.org/journal/ojra (accessed 28 August 2014).
14. Schlesinger N,. Canakinumab in gout. Expert Opin Biol Ther 2012; 12: 1265-75.